Detalhe da pesquisa
1.
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
N Engl J Med
; 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38739079
2.
Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human MYBPC3 HCM.
Circ Res
; 132(5): 628-644, 2023 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36744470
3.
Anderson-Fabry disease management: role of the cardiologist.
Eur Heart J
; 45(16): 1395-1409, 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38486361
4.
Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe.
Eur Heart J
; 45(7): 538-548, 2024 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38195003
5.
MYBPC3-c.772G>A mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy.
J Mol Cell Cardiol
; 191: 27-39, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38648963
6.
Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry.
Circulation
; 148(5): 394-404, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37226762
7.
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
J Card Fail
; 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38493832
8.
Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal.
Heart Fail Rev
; 29(2): 431-444, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38006470
9.
Electrocardiographic abnormalities in patients with cardiomyopathies.
Heart Fail Rev
; 29(1): 151-164, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37848591
10.
Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes.
J Med Genet
; 60(7): 722-731, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36543533
11.
Effect of Migalastat on cArdiac InvOlvement in FabRry DiseAse: MAIORA study.
J Med Genet
; 60(9): 850-858, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36669872
12.
Determinants of health status in older patients with transthyretin cardiac amyloidosis: a prospective cohort study.
Aging Clin Exp Res
; 36(1): 89, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598143
13.
Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments.
Eur Heart J
; 44(8): 656-667, 2023 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36582184
14.
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.
Eur Heart J
; 44(44): 4622-4633, 2023 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37804245
15.
Inflammation across the spectrum of hypertrophic cardiac phenotypes.
Heart Fail Rev
; 28(5): 1065-1075, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37115472
16.
Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy.
Eur Heart J Suppl
; 25(Suppl C): C173-C178, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37125268
17.
Stage-specific therapy for hypertrophic cardiomyopathy.
Eur Heart J Suppl
; 25(Suppl C): C155-C161, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37125313
18.
Frailty and caregiver relationship quality in older patients diagnosed with transthyretin cardiac amyloidosis.
Aging Clin Exp Res
; 35(6): 1363-1367, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129709
19.
Validation of a multiplelead smartphone-based electrocardiograph with automated lead placement for layman use in patients with hypertrophic cardiomyopathy.
J Electrocardiol
; 79: 1-7, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36893506
20.
Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator.
Eur Heart J
; 43(32): 3041-3052, 2022 08 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35766180